Key Highlights
- The FDA decision date for Opus Genetics and Viatris (NASDAQ:VTRS) phentolamine ophthalmic solution is October 17, 2026, according to a PDUFA calendar, so the outcome is still pending.
- Roche's Enspryng has an FDA date of October 15, 2026, two days earlier, though the calendar does not list a US ticker for Roche and no tag is used here.
- The Daiichi Sankyo and Merck ifinatamab deruxtecan BLA was withdrawn, so no FDA decision is expected on October 10, a date that appeared on some earlier calendars.
- Dates come from calendar sites and not from the FDA itself, so Viatris (NASDAQ:VTRS) investors should confirm each date in company releases before relying on it.
The Decision Dates
Two FDA dates are close. Enspryng, a Roche medicine, has a decision date of October 15, 2026, and the phentolamine ophthalmic solution being developed by Opus Genetics with Viatris (NASDAQ:VTRS) has a date of October 17. A third item, the Daiichi Sankyo and Merck Biologics license application for ifinatamab deruxtecan, was withdrawn, so no decision is expected on October 10. These dates come from review calendars, not from agency statements, and the tickers of the partners were not listed. A PDUFA date is the target by which the FDA aims to act, and the agency can approve, reject or ask for more information, and it sometimes acts early or extends the date.
What Is at Stake
Phentolamine ophthalmic solution is an eye drop under review, and the filing is a collaboration between Opus Genetics and Viatris (NASDAQ:VTRS), which has rights to commercialize it. Viatris is a large generic and specialty drug maker, so one eye drop is unlikely to change its financial profile much, while for the smaller partner the decision may be far more important. An approval would let the companies launch, and a complete response letter would delay launch while they address the FDA's concerns. The Withdrawal of the Daiichi and Merck filing shows that dates on calendars can disappear, which is why a pending date is a possibility, not a result, and no outcome should be assumed.
Risks and What to Watch
The main risks are a delay, a rejection or conditions on the label, and the outcome can differ from what a calendar suggests. Investors should watch for company releases around October 15 and October 17, 2026, and for an FDA action letter. Broader market conditions also matter: the Nasdaq Composite fell 1.25% in the latest session and September CPI arrives on October 14, so even good news can be muted. Viatris (NASDAQ:VTRS) has other catalysts, but none are stated here. Readers should treat the calendar dates as unconfirmed, and should not assume that an approval is likely, because the FDA decides on the evidence in the filing, which is not described in the file.
Where Things Stand
The FDA is expected to act on the Opus Genetics and Viatris eye drop on October 17, 2026, two days after the Enspryng date, but these dates come from calendars and the outcome is unknown. The withdrawn Daiichi and Merck filing is a reminder that dates can change. Viatris (NASDAQ:VTRS) should be judged on the actual FDA action. Investors should wait for confirmation in company filings and the next trading sessions before drawing conclusions, since the file labels this item as reported.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...